Chris Pak, Ph.D.

Chairman and Chief Executive Officer

Dr. Chris Pak is a biotechnology entrepreneur, pharmaceutical executive, and radiopharmaceutical innovator with more than 30 years of experience spanning biopharmaceutical research, drug development, molecular targeting, and translational medicine.

Throughout his career, Dr. Pak has helped advance innovative therapeutic candidates from scientific discovery toward clinical application. He has contributed to more than 20 Investigational New Drug (IND) applications, authored or co-authored in more than 90 scientific publications, and is an inventor on numerous patents. Earlier in his career, he held scientific and leadership positions at Centocor, now part of Johnson & Johnson, where he gained extensive experience in pharmaceutical research and development.

Dr. Pak spearheaded the development of EvaThera™, the company’s proprietary Evans Blue (EB)-based pharmacokinetic engineering platform. Designed to complement molecular targeting, EvaThera™ leverages reversible albumin binding and prolonged circulation to enhance tumor delivery, exposure, and retention of targeted radiopharmaceuticals. The platform represents MTTI’s approach to engineering pharmacokinetic properties to advance the development of targeted radiotherapeutics and theranostic medicines.

In recognition of its innovation, EvaThera™ was named “Radiopharmaceutical Therapy Solution of the Year 2026” by Pharma Tech Outlook, highlighting the platform’s potential in the evolving field of targeted radiopharmaceutical development.

Dr. Pak’s honors include being named a 2019 Ernst & Young Entrepreneur of the Year finalist for Greater Philadelphia, receiving the Ben Franklin Emerging Business Award, and being included on the State University of New York Alumni Honor Roll. In 2019, he was also invited to serve as Commencement Speaker at the State University of New York at Plattsburgh.

Norman LaFrance, MD, ME, FACP, FACNP, FACNM

Chief Medical Strategy Officer

Dr. LaFrance joined MTTI as Chief Medical Strategy Officer in January 2026. He has over 40 years of deep radiopharmaceutical experience as both a nuclear medicine physician and pharmaceutical executive. He previously served as Y-mAbs as Chief Development Officer,  Chief Medical Officer, Senior Vice President of PLUS Therapeutics, Inc., and prior to that, as Chief Medical Officer at Jubilant Pharma Ltd. Earlier, Dr. LaFrance served as Global Chief Medical Officer at IBA Molecular and earlier, as Senior Vice President and Chief Medical Officer of Molecular Insight Pharmaceuticals, Inc. Dr. LaFrance practiced medicine and held academic faculty appointments at Johns Hopkins University School of Medicine. He is Double Board Certified with Fellowship status both in internal medicine and nuclear medicine. Dr. LaFrance received his B.S and Master of Engineering degrees in nuclear engineering and science from Rensselaer Polytechnic Institute, and his M.D. from the University of Arizona, College of Medicine, Tucson. Dr. LaFrance has a long, distinguished and commercially successful record of drug research and development with numerous successful IND’s, Phase 1-4 trials, NDA’s, BLA’s, sNDA’s, LCM, MOB and multiple product approvals generating billions of revenue dollars.

Jeffrey A. Mattis, PhD

Senior Vice President of Scientific & Regulatory Affairs, Board Director

Dr. Mattis is a biopharmaceutical executive with more than 30 years’ experience in the technical development of biopharmaceuticals. Dr. Mattis previously served as Vice President of Pharmaceutical Development for Centocor. Dr. Mattis was instrumental in the technical development of several biopharmaceuticals approved for the US and multinational markets. These include ReoPro®, an anti-platelet drug for use in coronary angioplasty; Remicade®, a drug for treatment of Crohn’s disease and rheumatoid arthritis; and Myoscint®, a cardiac imaging agent.

Brian D. Gray, PhD

Senior Vice President of Research

Dr Gray has more than 25 years’ experience in the design and synthesis of novel compounds for biomedical research, diagnostics and drug delivery, with special expertise in fluorescent dyes and lipophilic agents. Following a research career at SmithKline Beckman, Dr. Gray co-founded Zynaxis, Inc., a biotech, as Director of Medicinal Chemistry. Later as V.P. of Chemical Research for PTI Research, Inc., he provided contract and custom chemistry services for life sciences and designed novel research reagents for neuronal tract tracing (NeuroVue® dyes) and cell tracking (CellVue® dyes). Dr. Gray earned a Ph.D. from the University of Dundee, Scotland, and carried out post-doctoral research in complex organic molecule synthesis at Oregon State University. He has been Principal Investigator in multiple grants.

Michael Silvon, PhD, MBA

Senior Vice President of Business Development

Dr. Silvon has driven profitable, pragmatic life sciences operations over the breadth of small and large molecule drug development; creating, fixing and growing multiple high science, heavily regulated businesses as a senior executive for Charles River Labs, Bioanalytical Systems and ICI/Zeneca. He orchestrated six acquisitions and integrated and ran businesses for three of these long-term. As VP Global Biopharmaceutical Services for Charles River Labs, he restructured and consolidated five global sites into a global leader in molecular biology, virology and microbiology services. Mike serves as Executive Chair for Sannova Analytical, a Private Equity funded CRO, and also served in Director and operating roles with Chronic Airways Therapeutics, Claro Labs, and Spark Insights. Mike is also a member of the American Lung Association Covid-19 Advisory Panel.

John M. Farah, Jr., PhD

Executive Advisor

Dr. Farah has broad expertise in life sciences business development, strategic analysis, R&D, ex-US commercialization, and scientific/clinical affairs, with a focus on products for hematology & oncology, neurosciences & pain, and infectious/inflammatory disorders.

It was through various operational- and executive roles within pharma, most notably at Cephalon, Inc., that Dr. Farah acquired extensive corporate experience in product and technology in- and out-licensing and acquisition; medical technology and market assessment in support of product development and licensing; and commercialization planning.

Through consultancy, Dr. Farah has advised clients on drug and biologic product development, corporate partnering strategies, licensing deals, and patent/license disputes. He has organized key opinion leader advice and support. Dr. Farah currently serves as an independent director at Pond Technologies, an ESG company addressing global sustainability challenges. As an industry advisory board member for the Coulter-Drexel Translational Research Partnership Program, Dr. Farah advises faculty applicants and awardees on advancing innovative technologies from clinical application to commercialization. Dr. Farah is a co-author and co-inventor on over 40 publications, whitepapers, and patents.